PF-07820435
- Generic Name
- PF-07820435
Praxis Therapeutics' Essential Tremor Drug Faces Setback in Phase 3 Interim Analysis
• Praxis Therapeutics announced that their lead drug candidate for essential tremor failed to meet primary endpoints in an interim Phase 3 analysis, marking a significant setback for the company's development program.
• Despite the disappointing interim results, the company has decided to continue the Phase 3 trial to completion, citing the need for comprehensive data analysis and potential insights from the full study population.
• Essential tremor remains a challenging neurological condition with limited treatment options, highlighting the continued unmet medical need in this therapeutic area.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath